CEACAM20 Inhibitors
CEACAM20 inhibitors are compounds that can indirectly affect the functional activity of CEACAM20, a protein involved in cell adhesion and signaling. These inhibitors target various signaling pathways that are upstream or regulatory of the processes in which CEACAM20 is involved. For example, EGFR inhibitors like erlotinib and gefitinib can downregulate the EGFR pathway, which is integral to the signaling cascade that influences cell proliferation and adhesion. By hindering EGFR, these inhibitors can indirectly affect the functional activity of CEACAM20 as it plays a role in these cellular processes. Similarly, inhibitors that target kinases such as RAF, Src, and BCR-ABL, like sorafenib, dasatinib, and nilotinib respectively, can modulate the signaling environment in which CEACAM20 operates. These kinases are part of larger signaling networks that, when inhibited, can lead to a reduction in the phosphorylation status and activation of downstream effectors that mediate cell adhesion and migration, subsequently influencing CEACAM20's activity.
Additionally, multi-targeted tyrosine kinase inhibitors such as sunitinib, pazopanib, and lenvatinib can have a broader impact on the signaling pathways that affect CEACAM20 function. These inhibitors can lead to a widespread alteration in the signaling milieu, including pathways that dictate cell adhesion and signaling dynamics, thus indirectly dampening CEACAM20 activity. For instance, by inhibiting VEGFR, as vandetanib does, the angiogenic signals and possibly related adhesion signals can be diminished, which might impact CEACAM20's involvement in these processes. Moreover, crizotinib's inhibition of ALK signaling can also lead to reduced adhesion-related signaling, potentially attenuating CEACAM20's activity in these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that can indirectly inhibit CEACAM20 by downregulating the EGFR pathway. Since CEACAM20 is known to be involved in cell adhesion and signaling, inhibition of EGFR can lead to a decrease in cell proliferation signals that can reduce the functional activity of CEACAM20 in cell-cell adhesion. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor that can indirectly inhibit CEACAM20 activity by blocking EGFR tyrosine kinase, which is upstream of many signaling pathways including those involving cell adhesion molecules like CEACAM20. As a result, the inhibition of EGFR can diminish the intracellular signals required for CEACAM20-mediated cell adhesion. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor that obstructs the RAF/MEK/ERK signaling pathway. Since CEACAM20 is implicated in cellular signaling, disrupting this pathway can lead to reduced signaling for molecules involved in adhesion, potentially diminishing CEACAM20's activity indirectly. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that can inhibit CEACAM20 indirectly by inhibiting pathways that involve cell adhesion and migration. By inhibiting receptor tyrosine kinases, it can alter the cellular signaling environment that affects CEACAM20 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL kinase inhibitor that can also inhibit Src family kinases. Src family kinases can phosphorylate substrates that are involved in adhesion. Thus, dasatinib can indirectly inhibit CEACAM20 by modulating the phosphorylation status of proteins that interact with or regulate CEACAM20. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual inhibitor of EGFR and HER2/neu that can indirectly inhibit CEACAM20 by affecting signaling pathways that involve cell proliferation and adhesion, potentially altering CEACAM20-related signaling. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a VEGFR inhibitor that can indirectly inhibit CEACAM20 by obstructing angiogenesis and reducing signals that may involve CEACAM20 in processes such as vascular remodeling, which can influence cell adhesion and signaling. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-tyrosine kinase inhibitor that can indirectly inhibit CEACAM20 by altering the signaling environment of pathways where CEACAM20 is involved, particularly those related to cell adhesion and migration. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib is a multi-kinase inhibitor that can indirectly inhibit CEACAM20 by affecting various signaling pathways, including those involving growth factors that could impact CEACAM20's role in cell signaling and adhesion. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective BCR-ABL inhibitor that can indirectly inhibit CEACAM20 by modifying the kinase activity that influences cell signaling and adhesion molecules, potentially affecting CEACAM20's functional activity in these processes. | ||||||